• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2009; 4(10): e7382.
Published online Oct 8, 2009. doi:  10.1371/journal.pone.0007382
PMCID: PMC2753647

Tumor-Shed PGE2 Impairs IL2Rγc-Signaling to Inhibit CD4+ T Cell Survival: Regulation by Theaflavins

Joseph Alan Bauer, Editor

Abstract

Background

Many tumors are associated with decreased cellular immunity and elevated levels of prostaglandin E2 (PGE2), a known inhibitor of CD4+ T cell activation and inducer of type-2 cytokine bias. However, the role of this immunomodulator in the survival of T helper cells remained unclear. Since CD4+ T cells play critical roles in cell-mediated immunity, detail knowledge of the effect tumor-derived PGE2 might have on CD4+ T cell survival and the underlying mechanism may, therefore, help to overcome the overall immune deviation in cancer.

Methodology/Principal Findings

By culturing purified human peripheral CD4+ T cells or Jurkat cells with spent media of theaflavin- or celecoxib-pre-treated MCF-7 cells, we show that tumor-shed PGE2 severely impairs interleukin 2 receptor γc (IL2Rγc)-mediated survival signaling in CD4+ T cells. Indeed, tumor-shed PGE2 down-regulates IL2Rγc expression, reduces phosphorylation as well as activation of Janus kinase 3 (Jak-3)/signal transducer and activator of transcription 5 (Stat-5) and decreases Bcl-2/Bax ratio thereby leading to activation of intrinsic apoptotic pathway. Constitutively active Stat-5A (Stat-5A1*6) over-expression efficiently elevates Bcl-2 levels in CD4+ T cells and protects them from tumor-induced death while dominant-negative Stat-5A over-expression fails to do so, indicating the importance of Stat-5A-signaling in CD4+ T cell survival. Further support towards the involvement of PGE2 comes from the results that (a) purified synthetic PGE2 induces CD4+ T cell apoptosis, and (b) when knocked out by small interfering RNA, cyclooxygenase-2 (Cox-2)-defective tumor cells fail to initiate death. Interestingly, the entire phenomena could be reverted back by theaflavins that restore cytokine-dependent IL2Rγc/Jak-3/Stat-5A signaling in CD4+ T cells thereby protecting them from tumor-shed PGE2-induced apoptosis.

Conclusions/Significance

These data strongly suggest that tumor-shed PGE2 is an important factor leading to CD4+ T cell apoptosis during cancer and raise the possibility that theaflavins may have the potential as an effective immunorestorer in cancer-bearer.

Introduction

Prostaglandins are lipid molecules regulating numerous processes including modulation of immune function [1][3]. PGE2 is produced by many different cell types, including malignant cells, and is known to contribute to cellular immune suppression in cancer patients [4], [5]. On the other hand, deletion of the respective prostaglandin receptors leads to reduced carcinogenesis and enhanced antitumor immunity [6].

Current paradigms suggest that CD4+ T cells play critical roles in the optimal induction and maintenance of clinically beneficial tumor immunity [7], [8]. These cells prime CTL-mediated antitumor responses [9] by preventing activation-induced cell death and functioning as antigen-presenting cells for CTLs to preferentially generate immune memory cells [10], [11]. CD4+ helper T cells also induce CD8+ cytotoxic T cell responses through dendritic cell activation by CD40/CD40L interactions [12] and determine the magnitude and persistence of such responses as well as CD8+ T cell infiltration of tumors [13]. Therefore, in order to establish itself, a growing tumor tries to overpower CD4+ T cells. It has been reported that both human patients and experimental animals with advanced cancer often exhibit a poorly functioning immune system [14]-[19]. There is evidence of increased apoptosis among CD4+ T cells in peripheral blood lymphocytes from cancer patients and animal models [20], [21]. Understanding the mechanisms of tumor-induced CD4+ T cell apoptosis as well as its amelioration by any biological response modifier is, therefore, of high importance from the point of view of amelioration of tumor-induced immuno-suppression.

Chemnitz et al. [22] have reported impairment in CD4+ T cell activation in cancer patients by PGE2. Tumor-shed PGE2 has been found to mediate profound alteration in cytokine balance in the cancer microenvironment and thereby contributing to T cell suppression in cancer patients [23], [24]. In fact, IL2 and IL2Rγc gene expression, that play crucial role in T cell proliferation, survival, and programmed cell death [25], are both targets of PGE2-induced suppression [26], [27], possibly through the inhibition of early events in T-cell signaling that include calcium influx and phosphatidylinositol breakdown [28], [29]. Moreover, PGE2 has been reported to down-regulate Jak-3 protein, which associates with IL2R, in T cells [26], [27]. This reduction in Jak-3 resulted in impaired phosphorylation and DNA binding activity of Stat-5 [26], [27]. Because Jak-3 is critical to IL2-dependent signaling and proliferation, its sensitivity to PGE2 may make it a prime target for suppressing IL2-dependent cell cycle progression in T cells. It is well accepted that Jak-mediated survival signals modulate Bcl-2 family of anti-apoptotic proteins [30]. Studies with Jak-3 deficient mice have showed down-regulation of Bcl-2 in CD8+ T cell population in thymus [31]. Other reports have demonstrated correlation between loss in Bcl-2 expression and death of T cells [32].

Interestingly, although PGE2 has been implicated in the increase or the acceleration of the programmed cell death process of immature CD4+CD8+CD3+ thymocytes in culture [33], CD4+CD8+ thymocytes inside the thymus in mice [34], and favors Th2-like cytokine secretion profiles in murine and human CD4+ T cells [35], there is no detail report on its effect on CD4+ T cell survival, if any, and the underlying mechanism. Since these helper T cells play critical roles in the optimal induction and maintenance of clinically beneficial tumor immunity [7], [8], here we address the role tumor-derived PGE2 might have on CD4+ T cell survival. Using exclusively primary human CD4+ T cells we found a correlation between over-expression of PGE2 in tumor cells and tumor-induced CD4+ T cell apoptosis. Inhibitory effects of tumor-shed PGE2 were in fact dependent on impairment of IL2Rγc signaling that lead to down regulation of IL2Rγc, reduced phosphorylation of Jak-3 and Stat-5A and decreased expression of pro-survival protein Bcl-2. Additionally, we demonstrated release of cytochrome c from mitochondria to cytosol and activation of caspase cascade. It was interesting to note that theaflavins, the black tea polyphenols, protected IL2Rγc signaling in CD4+ T cells from tumor-secreted PGE2 insult by inhibiting Cox-2 expression and subsequent PGE2 release from tumor cells. That these effects occurred in the absence of tumor cell-T cell contact negated the possibility of tumor contact-dependent CD4+ T cell apoptosis and highlighted PGE2 as an important mediator of impaired cellular immunity in patients with cancer.

There are ample evidences demonstrating the biological impact of theaflavins. These bioactive flavonoids of black tea have been reported to induce cell growth inhibition and apoptosis in a variety of cancer cells [36][38] Theaflavins also exert a plethora of beneficial effects on the cardiovascular system [39] and play a role in decreased intestinal cholesterol absorption thereby being responsible for lowering blood-cholesterol [40]. Antioxidative properties of theaflavins are manifested by their ability to inhibit free radical generation, scavenge free radicals and down-regulate the activity of pro-oxidative enzymes [41]. They can also influence activation of transcription factors such as NFkappaB or AP-1 [41]. However, there was hardly any report suggesting the immunoprotective effect of theaflavins. Our findings signify that theaflavins can be a possible therapeutic agent with a strong immunomodulatory effect and therefore, in future can be used alone or in combination with tumoricidal drugs to treat patients with cancer.

Results

Cell-free tumor supernatant leads to CD4+ T cell depletion by inducing apoptosis

When purified CD4+ T cells were cultured in the presence of cell-free breast cancer cell (MCF-7) supernatants (Fig. 1A), a situation mimicking the tumor-bearing condition in which tumor-shed mediators influence the circulating CD4+ T cell repertoire, increase in the percent of dead CD4+ T cell (43.2%) in comparison to control (7.2%) was recorded. Interestingly, when these T cells were co-incubated with theaflavin-pretreated tumor culture supernatants, significant protection from tumor-induced death was observed in a theaflavin-dose-dependent manner, the optimum effect being at 25 µg/ml theaflavins (11.6% dead cells), beyond which no further significant change could be obtained (Fig. 1A). Subsequent studies were, therefore, carried out with this dose of theaflavins.

Figure 1
Cell free tumor supernatant leads to CD4+ T cell depletion by inducing apoptosis.

Depletion in CD4+ T cell populations by tumor supernatant prompted us to investigate the underlying cause. Next, to assess the mode of cell death, we used three-color flow cytometry (FITC-CD4, PE-Annexin-V and 7AAD). Results of Figure-1B depict that while cell-free MCF-7 supernatants caused apoptosis to human peripheral CD4+ T cells (38.4% in supernatant-treated cells and 5.5% in control) as well as Jurkat cells (42.5% in supernatant-treated cells and 8.2% in control), theaflavins furnished protection to them. Interestingly, theaflavins did not change CD4+ cell numbers significantly when applied directly to control CD4+ T cells (Fig. 1B).

Tumor-shed PGE2 is responsible for CD4+ T cell apoptosis

All the reactions so far defined occurred independent of direct contact of CD4+ cells with tumor cells or even proximity thereby pointing towards the possibility of the presence of tumor-shed soluble immunosuppressors in the supernatant. Our search revealed a significant increase in PGE2 in tumor supernatant in a time-dependent manner with a maximum at 72 hours of continuous culture while media from theaflavins-treated MCF-7 cells contained significantly lower levels of this immunosuppressor (Fig. 2A). Moreover, percent CD4+ cell apoptosis was positively correlated (r = 0.964) with the PGE2 level of individual supernatant (Fig. 2B), whereas theaflavin-pre-treated tumor supernatants failed to induce significant death. Importantly, insertion of Cox-2-siRNA in tumor cells blocked the increase in PGE2 in cell-free tumor supernatant overtime (Fig. 2A). This suggested inhibition in the generation and/or release of PGE2 that resulted in lesser killing of CD4+ cells than untreated ones (Fig. 2B). All these data confirmed the role of Cox-2-derived PGE2 in tumor-induced CD4+ T cell killing. These results prompted us to explore the possibility of theaflavins to inhibit PGE2 production in tumor cells. Results of Figure 2 indeed depicted that theaflavin-treated tumor cells secreted significantly low level of PGE2 (Fig. 2A) that displayed lesser CD4+ cell killing (Fig. 2B)

Figure 2
Tumor-shed PGE2 is responsible for CD4+ T cell apoptosis.

PGE2 perturbs IL2Rγ-signaling events in CD4+ T cells

It is known that IL2 is essential for T cell homeostasis and activation for which it depends on IL2Rγc signaling [42], [43]. Thus, γc down regulation, if any by tumor-secreted PGE2, may fail to support T cells that then become susceptible to apoptotic death [43]. In our experimental model, we observed a marked decrease in the surface expression (Fig. 3A) as well as total amount (Fig. 3B) of IL2Rγ chain in CD4+ T cells that were co-incubated with tumor supernatants (Fig. 3A). Receptor expression in CD4+ T cells could be efficiently restored back to normal level by theaflavin-treatment of tumor cells (Fig. 3A and 3B).

Figure 3
Tumor-PGE2 perturbs IL2Rγc signaling events in CD4+ T cells.

It has been shown that Jak-3 is required to activate IL2R pathway for T cell proliferation [44] and loss of Jak-3 expression or kinase activity results in impaired activation of the IL2R signaling pathway [45]. Moreover, it is acknowledged that IL2Rγc is the primary mediator of cytokine signaling and activates Jak-3/Stat-5 signaling cascade [46] by Jak/Stat phosphorylation and subsequent translocation of phospho-Stat to nucleus [47]. We observed that, of the Jak proteins and associated Stat proteins, phosphorylations of Jak-3 and Stat-5 were down regulated in CD4+ T cells (Fig. 3B–C) by tumor-shed PGE2 (Fig. 2A), which could be ameliorated by pre-treatment of the tumor cells with theaflavins (Fig. 3B–C). To test whether Stat-5 was phosphorylated by Jak-3, we co-immunoprecipitated Stat-5 with anti-Jak-3 antibody, and the immunopurified proteins were then Western-blotted with anti-phospho-Stat-5 antibody. Results of Figure 3D showed that tumor supernatant substantially reduced association of phospho-Stat-5 with Jak-3 in CD4+ T cells. Perturbation in phospho-Stat-5 nuclear translocation activity was also observed in tumor-exposed CD4+ T cells in comparison to its untreated counterparts (Fig. 3E). Perturbation in phospho-Stat-5 nuclear translocation activity was also observed in tumor-exposed CD4+ T cells in comparison to its untreated counterparts (Fig. 3E). Interestingly, when CD4+ cells were cultured in presence of theaflavin-pretreated tumor cell supernatants, significant protection towards IL2Rγc/Jak-3/Stat-5 signaling i.e., up-regulation of γc expression, Jak-3/Stat-5 association and phosphorylation as well as nuclear localization of Stat-5 (Fig. 3B–E), was observed in CD4+ T cells, which offered them relive from the apoptotic insult that was observed with untreated tumor supernatant (Fig. 2B).

Stat-5A transfection confers resistance to CD4+ T cells from tumor-induced death

After confirming the Stat-5-mediated pathway as the major pathway in tumor-induced CD4+ T cell apoptosis, we undertook two different approaches to identify the isoform(s) of Stat-5 involved since both Stat-5A and Stat-5B isoforms play critical role in Bcl-2 induction in T cells. Results of Figure-4A depict that PGE2 present in cell-free tumor supernatant (Fig. 2A) significantly inhibited the phosphorylation of Stat-5A (Fig. 4A, left panel) but not that of Stat-5B (Fig. 4A, right panel). In this situation too, prior treatment of the tumor cells with theaflavins could bring back the phosphorylation status of Stat-5A to normal level in CD4+ T cells (Fig. 4A, left panel).

Figure 4
Stat-5A transfection confers resistance to CD4+ T cells from tumor-induced death.

To further confirm the role of two Stat-5 isotypes in tumor-induced CD4+ T cell demise, Jurkat T cells were over-expressed with wild-type Stat-5A/Stat-5B, C-terminal truncated dominant negative Stat-5 (Stat-5A713 and Stat-5B718) or constitutively active Stat-5A (Stat-5A1*6) genes (Fig. 4B) and then incubated with tumor-culture supernatants. Multiple experiments demonstrated that unlike wild-type cells, constitutively active Stat-5A1*6-transfected cells were only minimally affected, with an average of only 6–10% of the transfected cells succumbing to a tumor-supernatant-induced apoptotic death and theaflavins were able to protect them further (Fig. 4B). On the other hand, when dominant negative Stat-5A713 was introduced into Jurkat T cells, this protein rendered these cells more susceptible to tumor-induced death that could not be successfully prevented by theaflavin-administration. In contrast, theaflavins were able to protect Stat-5B718-transfected Jurkat T cells from tumor-induced death (Fig. 4B). When wild-type Stat-5A was introduced into these cells, it was able give protection from tumor-induced death, by itself or in the presence of theaflavins (Fig. 4B). All these results strongly reconfirm our hypothesis that Stat-5A protects CD4+ T cells from tumor-induced apoptosis and theaflavins utilize this isoform of Stat-5 to assert its protective effect.

Tumor-shed PGE2 indulges a shift from pro-survival to pro-apoptotic environment in CD4+ T

It is acknowledged that the regulation of both pro- and anti-apoptotic Bcl-2 family proteins is dependent upon the IL2Rγ chain signals [43] involving Jak-3/Stat-5 cascade. Thus, γc down regulation and inhibition of Jak-3/Stat-5A signaling by PGE2 present in the tumor supernatant, as obtained here, may fail to support sustained Bcl-2 expression, leading to CD4+ T cells susceptibility towards apoptotic death. To verify this hypothesis, we examined the expression levels of anti-apoptotic Bcl-2 and pro-apoptotic Bax proteins in CD4+ T cells. Results of Figure-5A depict that tumor insult down-regulated Bcl-2 and up-regulated Bax thereby lowering the Bcl-2:Bax ratio and creating a pro-apoptotic environment in these helper cells. Moreover, the expression of Xiap (X-linked inhibitor of apoptosis protein), a member of the inhibitor of apoptosis family of proteins, was diminished in these T cells treated with tumor supernatant (Fig. 5A), making them more susceptible to execution by caspases, as Xiap is known to inhibit caspases-3, -7 and -9 [48].

Figure 5
Tumor-shed PGE2 indulges a shift from pro-survival to pro-apoptotic environment in CD4+ T cells.

To validate these results, Jurkat T cells were ectopically transfected with Bcl-2 construct. Multiple experiments demonstrated that although control T cells were highly sensitive to tumor supernatant, with an average of 42% of Jurkat cells testing positive for apoptosis, Bcl-2-transfected cells were only minimally affected, with an average of only 12% of the transfected cells succumbing to a tumor supernatant-induced apoptotic death (Fig. 5B). These results led us to ask the question whether over-expression of Xiap would also make these cells more resistant to tumor-induced death. In fact, when these cells were over-expressed with Xiap gene, less killing was observed (Fig. 5B).

It is appreciated that the increase in Bax may cause mitochondrial trans-membrane potential loss that results in the release of cytochrome c in CD4+ T cell cytosol leading to activation of caspase cascades and apoptosis [49]. The experiment depicted in Figure-5A clearly illustrates that culturing CD4+ T cells with MCF-7 cell free supernatant, a significant increase in cytochrome c level in cytosol was observed while in unexposed CD4+ T cell cytosol it was minimally detected (Fig. 5A). Infact, in the downstream, substantial activation of caspase-3 was observed in supernatant-treated CD4+ T cells. These results indicate a total impairment in IL2Rγc survival signaling in CD4+ T cells by tumor-secreted PGE2. All these factors were restored back to their original levels up on prior treatment of tumor cells with theaflavins (Fig. 5A) thereby protecting CD4+ cells from tumor-induced apoptosis.

Re-confirmation of PGE2 as the molecule behind tumor-induced perturbation in CD4+ T cell survival signaling

Finally, to re-confirm the role of tumor-shed PGE2 in materialising the CD4+ T cell killing effect of tumor, we undertook two approaches. In the first approach, when CD4+ T cells were cultured in presence of supernatants of tumor cells pre-treated with celecoxib or tranfected with Cox-2-siRNA. These treatments caused marked inhibition not only in Cox-2 expression (Fig. 6A, upper panel) but also in PGE2 production by the tumor cells (Fig. 6A, lower panel) and significant protection for the IL2Rγc signaling in CD4+ T cells i.e., up-regulation of γc expression, Jak-3/Stat-5 phosphorylation and increase in Bcl-2 level (Fig. 6B, upper panel), which offered these T cells relive from the apoptotic insult (Fig. 6B, lower panel). These findings were again validated in the second approach, in which treatment of CD4+ T cells with purified PGE2 down-regulated IL2Rγc survival signaling (Fig. 6B, upper panel) and induced apoptosis (Fig. 6B, lower panel). Results from these two approaches well confirmed the importance of tumor-shed PGE2 in impairment of IL2Rγc survival signal in CD4+ T cells that culminated to apoptosis. Above data also signify that normalization of this signaling pathway may be the mechanism by which theaflavins prevent tumor-induced caspase-3-dependent CD4+ T cell apoptosis.

Figure 6
Re-confirmation of PGE2 as the molecule behind tumor-induced perturbation in CD4+ T cell survival signaling.

Discussion

A functional immune system is a potential barrier to tumor development and progression. To evade immune mechanisms, many tumors release immunosuppressive factors that attain high concentration in situ and inhibit cell-mediated effector function. Suppression of immune responses, coupled with superior growth kinetics of tumor cells, enable the neoplasm to surpass the control capacity of the host, leading to progressive decreases in cell-mediated anti-tumor responses and accelerated disease [50]. Although the immune system possesses the means to respond to cancer, it often fails to control the spread of malignancy. The fact that numerous laboratories, including our own, find that T lymphocytes undergo the physiological changes associated with apoptosis following co-culture with various cancer cell lines, lends support to the notion that it is the cancer cells themselves that induce lymphocyte death [14], [27]. Recent studies suggest that human carcinoma cells of various origins can activate apoptosis in lymphocytes interacting with the tumor in vivo and in vitro [51][53]. This tumor-induced apoptosis of lymphocytes may have important implications for the success of therapeutic regimens, including vaccination strategies [54].

Ample evidence suggests that CD4+ T cells facilitate the activation and development of anti-tumor responses of CD8+ T cells by enhancing clonal expansion at the tumor site, preventing activation-induced cell death and functioning as antigen-presenting cells for CTLs to preferentially generate immune memory cells [10]. CD4+ T cells assist CD8+ T cell priming via the engagement of CD40-ligand (CD154) on CD4+ T cells and CD40 expressed on DC [55][57]. This interaction results in the activation and maturation of DC, making them competent to stimulate antigen-specific CD8+ T cell responses [58]. It is important to note that primary CD8+ T cell responses to nonmicrobial antigens, as in case of cancer, display an absolute dependence on CD4+ T cell help [59], [60]. In this regard, our understanding of the importance of CD4+ T cells in orchestrating immune responses has grown dramatically over the past decade [10]. Here we aimed at elucidating the mechanisms of the tumor-induced suppression of such ‘T-cell help’ and its amelioration by theaflavins.

It has been demonstrated that several carcinoma cell lines produce soluble factors that inhibit T cell proliferation. Because tumor-induced apoptosis of lymphocytes may be mediated by an array of death receptors co-expressed on T cells or by tumor-derived soluble factors, it is important to characterize those intracellular events that may be potential targets for therapeutic intervention to minimize T cell apoptosis since if the immune system of cancer patient is persistently compromised, the success of any kind of therapy would be limited unless the immune system can be appropriately stimulated.

PGE2 has been implicated as a potential inhibitor of T cell function in the context of malignant disease [61], [62]. Elevated levels of PGE2 have also been found in patients with Hodgkin's lymphoma, which is suggested to be partially responsible for decreased cellular immune function in these patients [4], [5]. Another report confirmed that tumor over-expression of PGE2 via the elaboration of Cox-2 directly blocks patient's defence mechanism against cancer and promote cancer growth [63]. It is well known that PGE2 has diverse effects on CD4+ T cells leading to inhibition of T cell activation [64]. Albeit the outcome of PGE2-signaling is well established, the molecular mechanisms involved are still not completely understood. The present study was designed to determine the potential mechanisms of tumor-derived PGE2 leading to CD4+ T cell apoptosis. We exclusively used primary human CD4+ T cells to achieve more physiologic conditions compared with cell line models defective in key enzymes of T cell signaling [65]. Our study demonstrated the presence of Cox-2 derived PGE2 in tumor supernatant and that the effect of tumor supernatant on CD4+ T cells bore remarkable similarities with the effects of PGE2 exposure on these cells. Analysis of data revealed that PGE2 present in cell free tumor supernatant interferes with one of the major pathways for survival and activation of CD4+ T cells. This interference affected γc expression, Jak-3/Stat-5 phosphorylation and Bcl-2 level suggesting an inhibition of early IL2Rγc-mediated signaling events in CD4+ cells. We showed that PGE2 leads to down-regulation of IL2Rγc expression and Jak-3 phosphorylation thereby inactivating the most proximal events of IL2Rγc signaling. Inability of externally added IL2 to overcome tumor-PGE2 effect indicated that IL2 deprivation is not the primary cause of CD4+ cell death in our system.

Alternatively, theaflavins, which inhibited Cox-2 expression and subsequent PGE2 production in tumor cells, efficiently ameliorated tumor-induced impairment of IL2Rγc signaling. Recovery of Jak/Stat signaling also altered Bcl-2:Bax ratio in these helper cells in favour of survival. These results are in contrary to those of Kolenko et al. [26] who showed that in renal cancer, impairment in IL2R signaling by PGE2 did not affect IL2-dependent induction of Bcl-2. However, studies with Jak-3−/− knockout mice showing impaired T cell development and severe down-regulation of Bcl-2 protein in T cell populations with moderate increase in Bax expression [66], [67] strengthened our findings. Interestingly, theaflavins offered better protection to T helper cells from tumor-induced death in comparison to either celecoxib or Cox-2-siRNA suggesting that along with PGE2, tumor-induced CD4+ T cell death might have other mediators that are independent of Cox-2 and inhibition of not only PGE2 but also those mediators by theaflavins could be the cause behind observed immunoprotection provided by these polyphenols.

In conclusion, our data provide direct evidence that tumor-derived Cox-2-dependent PGE2 affects IL2Rγc-driven signals in CD4+ T cells by down-regulating IL2Rγc and inactivating Jak resulting in impaired activation of downstream signals as shown by decreased phosphorylation of Stat. As a consequence, Stat phosphorylation and translocation to nucleus as well as anti-apoptotic Bcl-2 and Xiap protein expressions were decreased while increasing Bax thereby activating mitochondrial death cascade in these cells. The functional consequence is a state of CD4+ T cell depletion. Although CD4+ T cells are central to the function of the immune system, their role in tumor immunity remains under-appreciated. Recent advances in understanding of contribution of CD4+ in anti-tumor immunity, as well as some intriguing developments in the clinic, indicate that due to the cooperative role of CD4+ helper T cells for CD8+ cytotoxic T cells, they have the unrealized potential in tumor eradication. Based on our observations, we postulate PGE2 as an important factor responsible for impaired survival signaling in CD4+ T cells thereby leading them towards apoptosis in tumors associated with higher PGE2 production. In addition, our results demonstrating theaflavin-induced protection of IL2Rγc/Jak-3/Stat-5A signaling as well as survival of CD4+ T cells from tumor PGE2-insult signify that these plant polyphenols may have the potency to sustain the cell mediated immunity of the cancer-bearer that can be utilized for developing an effective therapy of this deadly disease.

Materials and Methods

Isolation of CD4+ T cells

Human venous blood from healthy adult volunteers was collected with informed consent using heparinized syringes. Whole blood (100 mL) was diluted with 150 mL of RPMI 1640 (Sigma, St Louis, MO, USA) and then layered in centrifuge tubes onto 120 mL of Histopaque-1077 (Sigma) gradient. After centrifugation the opaque interface containing lymphocytes was collected, washed twice in RPMI 1640 and, after complete supernatant removal, the pellet was re-suspended in PBS supplemented with 0.5% of BSA and 2 mmol/L EDTA. CD4+ T cells were purified from total leukocytes by positive selection using anti-CD4 antibody coated micro-beads (Milteny Biotech) [68]. The purity of the isolated CD4+ T cells was determined by flow cytometry and was routinely >99% CD3+ and CD4+, but was negative for CD8. Cells were cultured in RPMI 1640 (supplemented with 10 U/ml recombinant IL-2, 10% fetal bovine serum, 2 mM L-glutamine, 100 µg/ml sodium pyruvate, 100 µM non-essential amino acids, 100 µg/ml streptomycin and 50 U/ml penicillin; Sigma) at 37°C in humidified incubator containing 5% CO2. Viable cell numbers were determined by Trypan blue exclusion test. The Jurkat T cell line (maintained in complete RPMI 1640) and human mammary epithelial carcinoma cells (MCF-7, MDA-MB-231 and ZR-75-1; maintained in complete DMEM) were obtained from NCCS, India. Tumor supernatants freed from cellular components were used in 1[ratio]1 ratio with RPMI to study the effect of tumor supernatant on CD4+ T cells.

Tumor cells were pre-treated with different doses of theaflavins (6.25–50 µg/ml), as per the requirement of the experiment, for 90 min after which the culture media containing extra theaflavins were replaced by fresh media. Seventy two-hour old cell-free tumor supernatants were used in 1[ratio]1 ratio with RPMI for 48 h to study the effect of tumor on CD4+ T/Jurkat cells. To study the role of tumor-shed PGE2 on CD4+ T apoptosis, supernatants of Cox-2 inhibitor-treated (celecoxib; 50 µM) or Cox-2-siRNA-transfected tumor cells were used. In parallel sets of experiments CD4+ T cells were incubated with 3.5 ng/ml of prostaglandin E2 (Sigma).

Plasmid constructs, siRNA and transfections

Flag-tagged (N-terminus) cDNA encoding full length Stat-5A and Stat-5B, C-terminal truncated Stat-5A (amino acid 713; Stat-5A713) and Stat-5B (amino acids 718; Stat-5B718) (provided by Dr. J.N. Ihle of St. Jude Children's Research Hospital, TN), constitutively active mutant Stat-5A1*6 (generous gift from Prof. T. Kitamura, Institute of Medical Science, University of Tokyo, Japan), Bcl-2, Xiap in Prk5 vector (2 µg/million cells) were introduced separately into Jurkat T cell using T cell nucleofector kit (Amaxa, Koein, Germany). Isolation of stably expressing clones were done by limiting dilution and selection with IL2 (25 U/ml) and hygromycin B (800 mg/ml) for 14 days and cells surviving this treatment were cloned and assessed for Bcl-2 and Stat-5 expressions by Western blot analysis. Tumor cells were transfected with 300pmole of Cox-2-/control-ds-siRNA (Santa Cruz) and lipofectamine 2000 separately for 12 h. Levels of Cox-2 mRNA and protein were estimated by RT-PCR and Western blotting. Transfected cells were cultured for 72 h and cell free supernatants were collected for subsequent experiments.

Flow cytometry

For the determination of cell death, CD4+ T cells were labelled with 7-aminoactinomycin D (7-AAD) and Annexin-V-phycoerythrin (PE) (BD Bioscience) and analyzed on flow cytometer (FACS Calibur; Becton Dickinson), equipped with 488 nm Argon laser light source using CellQuest software. Electronic compensation of the instrument was done to exclude overlapping of the emission spectra. Total 10,000 events were acquired and cells were properly gated for analysis. Annexin-V+/7-AAD+/CD4+ cells were regarded as apoptotic cells. To determine the surface levels of IL2Rγc expression, CD4+ T cells were incubated with anti-IL2Rγc (2 µg/ml; Santa Cruz) antibody and then with FITC-conjugated 2nd antibody followed by flowcytometric analysis.

Co-immunoprecipitation and immunoblotting

Primary human CD4+ T cells were lysed in buffer (10 mM Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, and 0.5 mM DTT) and nuclei were pelleted by brief-centrifugation. The supernatant was spun at 105,000×g to get cytosolic fraction. The nuclear extract was prepared in buffer containing 20 mM HEPES, pH 7.9, 25% (v/v) glycerol, 420 mM KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, and 0.5 mM PMSF. For whole cell lysate, cells were homogenized in buffer (20 mM Hepes, pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM Na-EDTA and 1 mM DTT). All the buffers were supplemented with protease and phosphatase inhibitor cocktails [69], [70]. For direct Western blot analysis, cell lysates or the particular fractions containing 50 µg protein was separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membrane. The protein of interest was visualized by chemiluminescence.

For the determination of direct interaction between two proteins, co-immunoprecipitation technique was employed. The immunopurified proteins were then detected by Western blot using specific antibody (Santa Cruz). Equal protein loading was confirmed by re-probing the blots with α-actin/histone H1 antibody (Santa Cruz).

Prostaglandin E2 assay

PGE2 content in culture supernatants was determined using PGE2 ELIZA bioassay kit (US Biologicals) following the manufacturer's protocol.

Statistical Analysis

Values are shown as standard error of mean (SEM) except otherwise indicated. Comparison of multiple experimental groups was performed by 2-way ANOVA followed by a post-hoc Bonferroni multiple comparison test. Data were analyzed and, when appropriate, significance of the differences between mean values was determined by a Student's t test. Results were considered significant at p<0.05.

Acknowledgments

We are grateful to Dr. J.N. Ihle of St. Jude Children's Research Hospital, TN for Stat-5A, Stat-5B, Stat-5A713 and Stat-5B718 clones, and Prof. T. Kitamura, Institute of Medical Science, University of Tokyo, Japan for Stat-5A1*6. We thank Mr. U. Ghosh and Mr. R. Dutta for technical help.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by research grants from Department of Science and Technology, Council of Scientific and Industrial Research and Indian Council of Medical Research, Govt. of India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Phipps RP, Stein SH, Roper RL. A new view of prostaglandin E regulation of the immune response. Immunol Today. 1991;12:349–352. [PubMed]
2. Goetzl EJ, An S, Smith WL. Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. FASEB J. 1995;9:1051–1058. [PubMed]
3. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol. 2002;23:144–150. [PubMed]
4. Passwell J, Levanon M, Davidsohn J, Ramot B. Monocyte PGE2 secretion in Hodgkin's disease and its relation to decreased cellular immunity. Clin Exp Immunol. 1983;51:61–68. [PMC free article] [PubMed]
5. Cayeux SJ, Beverley PC, Schulz R, Dorken B. Elevated plasma prostaglandin E2 levels found in 14 patients undergoing autologous bone marrow or stem cell transplantation. Bone Marrow Transplant. 1993;12:603–608. [PubMed]
6. Yang L, Yamagata N, Yadav R, Brandon S, Courtney RL, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest. 2003;111:727–735. [PMC free article] [PubMed]
7. Toes RE, Ossendrop F, Offringa R, Melief CJM. CD4+ T cells and their role in antitumor immune responses. J Exp Med. 1999;189:753–756. [PMC free article] [PubMed]
8. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol. 1998;10:588–594. [PubMed]
9. Goedegebuure PS, Eberlein TJ. The role of CD4+ tumor-infiltrating lymphocytes in human solid tumors. Immunol Res. 1995;14:119–131. [PubMed]
10. Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev. 2008;222:129–144. [PubMed]
11. Huang H, Hao S, Li F, Ye Z, Yang J, et al. CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes. Immunology. 2007;120:148–159. [PMC free article] [PubMed]
12. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478–480. [PubMed]
13. Marzo AL, Lake RA, Robinson BW, Scott B. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res. 1999;59:1071–1079. [PubMed]
14. Das T, Sa G, Paszkiewicz-Kozik E, Hilston C, Molto L, et al. Tumors Induce T Cell Apoptosis Through Receptor-Dependent and Receptor-Independent Pathways. J Immunol. 2008;180:4687–4696. [PubMed]
15. Das T, Sa G, Hilston C, Kudo D, Rayman P, et al. GM1 and TNFa, overexpressed in renal cell carcinoma, synergize to induce T cell apoptosis. Cancer Research. 2008;68:2014–2023. [PubMed]
16. Sa G, Das T, Moon C, Hilston CM, Rayman PA, et al. GD3, an Overexpressed Tumor-Derived Ganglioside, Mediates the Apoptosis of Activated but not Resting T Cells. Cancer Res. 2009;69:3095–3104. [PMC free article] [PubMed]
17. Bhattacharyya S, Mandal D, Sen GS, Pal S, Banerjee S, et al. Tumor-induced oxidative stress perturbs NFκB activity augmenting TNFα-mediated T cell death: Protection by curcumin. Cancer Research. 2007;67:362–370. [PubMed]
18. Mandal D, Bhattacharyya S, Lahiry L, Chattopadhyay S, Sa G, et al. Black tea-induced decrease in IL-10 and TGF-β of tumor cells promotes Th1/Tc1 response in tumor-bearer. Nutrition Cancer. 2007;58:213–221. [PubMed]
19. Finke J, Ferrone S, Frey A, Mufson A, Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today. 1999;20:158–160. [PubMed]
20. Bhattacharyya S, Mandal D, Saha B, Sen GS, Das T, et al. Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem. 2007;282:15954–15964. [PubMed]
21. Mandal D, Bhattacharyya A, Lahiry L, Bhattacharyya S, Sa G, et al. Tumor-induced thymic involution via Inhibition of IL-7Rα and its JAK-STAT signaling pathway: Protection by Black Tea. Int. Immunopharmacol. 2005;6:433–444. [PubMed]
22. Chemnitz JM, Driesen J, Classen S, Riley JL, Debey S, et al. Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res. 2006;66:1114–1122. [PubMed]
23. Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol. 2004;11:328–339. [PubMed]
24. Minakuchi R, Wacholtz MC, Davis LS, Lipsky PE. Delineation of the mechanism of inhibition of human T cell activation by PGE2. J Immunol. 1990;145:2616–2625. [PubMed]
25. Spierings DC, Lemmens EE, Grewal K, Schoenberger SP, Green DR. Duration of CTL activation regulates IL2 production required for autonomous clonal expansion. Eur J Immunol. 2006;36:1707–1717. [PubMed]
26. Kolenko V, Rayman P, Roy B, Cathcart MK, O'Shea J, et al. Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine monophosphate-elevating agents: impact on interleukin-2 receptor signaling pathway. Blood. 1999;93:2308–2318. [PubMed]
27. Bhattacharyya S, Mandal D, Saha B, Sen GS, Das T, et al. Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem. 2007;282:15954–15964. [PubMed]
28. Anastassiou ED, Paliogianni F, Balow JP, Yamada H, Boumpas DT. Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL2 and IL2R alpha gene expression at multiple levels. J Immunol. 1992;148:2845–2852. [PubMed]
29. Alava MA, DeBell KE, Conti A, Hoffman T, Bonvini E. Increased intracellular cyclic AMP inhibits inositol phospholipid hydrolysis induced by perturbation of the T cell receptor/CD3 complex but not by G-protein stimulation. Association with protein kinase A-mediated phosphorylation of phospholipase C-gamma 1. Biochem J. 1992;284:189–199. [PMC free article] [PubMed]
30. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood. 1996;88:386–401. [PubMed]
31. Wen R, Wang D, McKay C, Bunting DK, Marini CJ, et al. Jak3 selectively regulates Bax and Bcl-2 expression to promote T-cell development. Mol Cell Biol. 2001;21:678–689. [PMC free article] [PubMed]
32. Webb LM, Vigorito E, Wymann MP, Hirsch E, Turner M. Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J Immunol. 2005;175:2783–2787. [PubMed]
33. Saiagh S, Rigal D, Monier JC. Effects of PGE2 upon differentiation and programmed cell death of suspension cultured CD4-CD8- thymocytes. Int J Immunopharmacol. 1994;16:775–786. [PubMed]
34. Mastino A, Piacentini M, Grelli S, Favalli C, Autuori F, et al. Induction of apoptosis in thymocytes by prostaglandin E2 in vivo. Dev Immunol. 1992;2:263–271. [PMC free article] [PubMed]
35. Hilkens CM, Vermeulen H, van Neerven RJ, Snijdewint FG, Wierenga EA, et al. Differential modulation of T helper type 1 (Th1) and T helper type 2 (Th2) cytokine secretion by prostaglandin E2 critically depends on interleukin-2. Eur J Immunol. 1995;25:59–63. [PubMed]
36. Lahiry L, Saha B, Chakraborty J, Bhattacharyya S, Chattopadhyay S, et al. Contribution of p53-mediated transcription-dependent pathway in mammary epithelial carcinoma cell apoptosis by theaflavins. Apoptosis. 2008;13:771–781. [PubMed]
37. Prasad S, Kaur J, Roy P, Kalra N, Shukla Y. Theaflavins induce G2/M arrest by modulating expression of p21waf1/cip1, cdc25C and cyclin B in human prostate carcinoma PC-3 cells. Life Sci. 2007;81:1323–1331. [PubMed]
38. Yang CS, Liao J, Yang GY, Lu G. Inhibition of lung tumorigenesis by tea. Exp Lung Res. 2005;31:135–144. [PubMed]
39. Dreger H, Lorenz M, Kehrer A, Baumann G, Stangl K, et al. Characteristics of catechin- and theaflavin-mediated cardioprotection. Exp Biol Med. 2008;233:427–433. [PubMed]
40. Vermeer MA, Mulder TP, Molhuizen HO. Theaflavins from black tea, especially theaflavin-3-gallate, reduce the incorporation of cholesterol into mixed micelles. J Agric Food Chem. 2008;56:12031–12036. [PubMed]
41. Łuczaj W, Skrzydlewska E. Antioxidative properties of black tea. Prev Med. 2005;40:910–918. [PubMed]
42. Alves NL, Arosa FA, van Lier RA. Common gamma chain cytokines: dissidence in the details. Immunol Lett. 2007;108:113–120. [PubMed]
43. Nakajima H, Shores EW, Noguchi M, Leonard WJ. The common cytokine receptor γ-chain plays an essential role in regulating lymphoid homeostasis. J Exp Med. 1997;185:189–195. [PMC free article] [PubMed]
44. Taniguchi T, Minami Y. The IL2/IL2 receptor system: A current overview. Cell. 1993;73:5–8. [PubMed]
45. Oakes SA, Candotti F, Johnson JA, Chen Y-Q, Ryan JJ, et al. Signaling via IL2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways. Immunity. 1996;5:605–615. [PubMed]
46. Witthuhn BA, Silvennoinen O, Miura O, Lai KS, Cwik C, et al. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature. 1994;370:153–157. [PubMed]
47. Zhang Q, Nowak I. Vonderheid EC, Rook AH, Kadin ME, et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA. 1996;93:9148–9153. [PMC free article] [PubMed]
48. Li C, Wu Z, Liu M, Pazgier M, Lu W. Chemically synthesized human survivin does not inhibit caspase-3. Protein Sci. 2008;17:1624–1629. [PMC free article] [PubMed]
49. Hengartner MO. The biochemistry of apoptosis. Nature. 2001;407:770–776. [PubMed]
50. Micallef MJ, Yoshida K, Kawai S, Hanaya T, Kohno K, et al. In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother. 1997;43:361–367. [PubMed]
51. Reichert TE, Rabinowich H, Johnson JT, Whiteside T. Mechanisms responsible for signaling and functional defects. J Immunother. 1998;21:295–306. [PubMed]
52. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Investig. 1997;99:1173–1178. [PMC free article] [PubMed]
53. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, et al. Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Investig. 1998;101:2579–2588. [PMC free article] [PubMed]
54. Saito T, Dworacki G, Gooding W, Lotze MT, Whiteside TL. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res. 2000;6:1351–1364. [PubMed]
55. Watanabe S, Kagamu H, Yoshizawa H, Fujita N, Tanaka H, et al. The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity. J Immunol. 2003;171:5828–5836. [PubMed]
56. Shreedhar V, Moodycliffe AM, Ullrich SE, Bucana C, Kripke ML, et al. Dendritic cells require T cells for functional maturation in vivo. Immunity. 1999;11:625–636. [PubMed]
57. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480–483. [PubMed]
58. Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, et al. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol. 2004;5:1143–1148. [PubMed]
59. Bevan MJ. Helping the CD8+ T- cell response. Nat Rev Immunol. 2004;4:595–602. [PubMed]
60. Wang JC, Livingstone AM. Cutting Edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo. J Immunol. 2003;171:6339–6343. [PubMed]
61. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005;65:5211–5220. [PubMed]
62. Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol. 2004;11:328–339. [PubMed]
63. Kolenko V, Wang Q, Riedy MC, O'Shea J, Ritz J, et al. Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL2 receptor signaling: role of soluble products from human renal cell carcinomas. J Immunol. 1997;159:3057–3067. [PubMed]
64. Goodwin JS, Bankhurst AD, Messner RP. Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell. J Exp Med. 1977;146:1719–1734. [PMC free article] [PubMed]
65. Astoul E, Edmunds C, Cantrell DA, Ward SG. PI 3-K and T-cell activation: limitations of T-leukemic cell lines as signaling models. Trends Immunol. 2001;22:490–496. [PubMed]
66. Baird AM, Thomis DC, Berg LJ. T cell development and activation in Jak3-deficient mice. J Leukocyte Biol. 1998;63:669–677. [PubMed]
67. Thomis DC, Berg LJ. Peripheral expression of Jak3 is required to maintain T lymphocyte function. J Exp Med. 1997;185:197–206. [PMC free article] [PubMed]
68. Anastassiou ED, Paliogianni F, Balow JP, Yamada H, Boumpas DT. Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL2 and IL2R alpha gene expression at multiple levels. J Immunol. 1992;148:2845–2852. [PubMed]
69. Bhattacharyya A, Lahiry L, Mandal D, Sa G, Das T. Black tea induces tumor cell apoptosis by Bax translocation, loss in mitochondrial transmembrane potential, cytochrome c release and caspase activation. Int J Cancer. 2005;117:308–315. [PubMed]
70. Choudhuri T, Pal S, Das T, Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem. 2005;280:20059–20068. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...